Co-Crystalization and In Vitro Biological Characterization of 5-Aryl-4-(5-Substituted-2-4-Dihydroxyphenyl)-1,2,3-Thiadiazole Hsp90 Inhibitors

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Sharp, Swee Y ^a   Roe, S Mark ^b,e   Kazlauskas, Egidijus ^c   Čikotiene, Inga ^c   Workman, Paul ^a   Matulis, Daumantas ^c   Prodromou, Chrisostomos ^d  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b Biochemistry and Molecular Biology   (United Kingdom)

^c VILNIUS UNIVERSITY   (Lithuania)

^d UNIVERSITY OF SUSSEX   (United Kingdom)

^e UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3 THIADIAZOLE DERIVATIVE; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; ICPD 26; ICPD 34; ICPD 47; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RAF PROTEIN; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CONTROLLED STUDY; CRYSTALLIZATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; PROTEIN DEPLETION; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; HSP27 HEAT-SHOCK PROTEINS; HSP72 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; THIADIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84866296533     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044642     Document Type: Article

References (48)

1. Ali MM, Roe SM, Vaughan CK, Meyer P, Panaretou B, et al. (2006) Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 440: 1013-1017.
2. Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, et al. (1996) Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A 93: 14536-14541.
3. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, et al. (2001) The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 3: 93-96.
4. Schulte TW, Neckers LM, (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42: 273-279.
5. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P, (1999) DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91: 1940-1949.
6. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA, (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61: 4003-4009.
7. Pacey S, Banerji U, Judson I, Workman P (2006) Hsp90 inhibitors in the clinic. Handb Exp Pharmacol: 331-358.
8. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, et al. (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23: 1078-1087.
9. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, et al. (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152-4161.
10. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, et al. (2011) HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clinical cancer research: an official journal of the American Association for Cancer Research 17: 5132-5139.
11. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, et al. (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 47: 291-302.
12. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, et al. (1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58: 2385-2396.
13. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, et al. (2005) Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65: 10006-10015.
14. Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, et al. (2004) Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 10: 4813-4821.
15. Ge J, Normant E, Porter JR, Ali JA, Dembski MS, et al. (2006) Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 49: 4606-4615.
16. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, et al. (2011) A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clinical cancer research: an official journal of the American Association for Cancer Research 17: 1561-1570.
17. Whitesell L, Lindquist SL, (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772.
18. Workman P, Burrows F, Neckers L, Rosen N, (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113: 202-216.
19. Chiosis G, (2006) Targeting chaperones in transformed systems-a focus on Hsp90 and cancer. Expert Opin Ther Targets 10: 37-50.
20. Xu W, Neckers L, (2007) Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 13: 1625-1629.
21. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
22. Mosser DD, Morimoto RI, (2004) Molecular chaperones and the stress of oncogenesis. Oncogene 23: 2907-2918.
23. Neckers L, Workman P, (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clinical cancer research: an official journal of the American Association for Cancer Research 18: 64-76.
24. Travers J, Sharp S, Workman P, (2012) HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug discovery today 17: 242-252.
25. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, et al. (2001) A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 8: 289-299.
26. Chiosis G, (2006) Discovery and development of purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 6: 1183-1191.
27. Cheung KM, Matthews TP, James K, Rowlands MG, Boxall KJ, et al. (2005) The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 15: 3338-3343.
28. Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, et al. (2007) In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 67: 2206-2216.
29. Smith NF, Hayes A, James K, Nutley BP, McDonald E, et al. (2006) Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Mol Cancer Ther 5: 1628-1637.
30. Dymock BW, Barril X, Brough PA, Cansfield JE, Massey A, et al. (2005) Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 48: 4212-4215.
31. Sharp SY, Prodromou C, Boxall K, Powers MV, Holmes JL, et al. (2007) Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 6: 1198-1211.
32. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, et al. (2008) 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51: 196-218.
33. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, et al. (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850-2860.
34. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, et al. (2008) NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10: R33.
35. Prodromou C, Nuttall JM, Millson SH, Roe SM, Sim TS, et al. (2009) Structural basis of the radicicol resistance displayed by a fungal Hsp90. ACS Chem Biol 4: 289-297.
36. Millson SH, Chua CS, Roe SM, Polier S, Solovieva S, et al. (2011) Features of the Streptomyces hygroscopicus HtpG reveal how partial geldanamycin resistance can arise with mutation to the ATP binding pocket of a eukaryotic Hsp90. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology.
37. Cikotiene I, Kazlauskas E, Matuliene J, Michailoviene V, Torresan J, et al. (2009) 5-Aryl-4-(5-substituted-2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone. Bioorg Med Chem Lett 19: 1089-1092.
38. Maloney A, Workman P, (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2: 3-24.
39. CCP4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760-763.
40. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
41. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
42. Murshudov GN, Vagin AA, Dodson EJ, (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255.
43. Laskowski RA, Hutchinson EG, Michie AD, Wallace AC, Jones ML, et al. (1997) PDBsum: a Web-based database of summaries and analyses of all PDB structures. Trends Biochem Sci 22: 488-490.
44. Delano WL (2002) The PyMol molecular graphics system. DeLano Scientific.
45. Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, et al. (2004) Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol 11: 775-785.
46. Prodromou C, Piper PW, Pearl LH, (1996) Expression and crystallization of the yeast Hsp82 chaperone, and preliminary X-ray diffraction studies of the amino-terminal domain. Proteins 25: 517-522.
47. Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, et al. (2002) Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 10: 1307-1318.
48. Howes R, Barril X, Dymock BW, Grant K, Northfield CJ, et al. (2006) A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem 350: 202-213.